147 related articles for article (PubMed ID: 17389531)
1. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.
Durand JP; Gourmel B; Mir O; Goldwasser F
Ann Oncol; 2007 Apr; 18(4):808-9. PubMed ID: 17389531
[No Abstract] [Full Text] [Related]
2. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
Howell JE; Szabatura AH; Hatfield Seung A; Nesbit SA
J Oncol Pharm Pract; 2008 Sep; 14(3):157-62. PubMed ID: 18719071
[TBL] [Abstract][Full Text] [Related]
3. [Treatment and prevention of iphosphamide-induced encephalopathy].
Sunela K; Bärlund M
Duodecim; 2016; 132(4):314-7. PubMed ID: 27017785
[TBL] [Abstract][Full Text] [Related]
4. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity.
Jarkowski A
Am J Health Syst Pharm; 2008 Dec; 65(23):2229-31. PubMed ID: 19020190
[TBL] [Abstract][Full Text] [Related]
5. Does neurokinin-1-receptor antagonist aprepitant diminish the efficacy of cyclophosphamide-based chemotherapy?
Paiva CE; Paiva BS; Michelin OC
Sao Paulo Med J; 2009 Nov; 127(6):385-6. PubMed ID: 20512296
[No Abstract] [Full Text] [Related]
6. Aprepitant-associated ifosfamide neurotoxicity.
Hansen Ho ; Yuen C
J Oncol Pharm Pract; 2010 Jun; 16(2):137-8. PubMed ID: 19759053
[No Abstract] [Full Text] [Related]
7. A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant.
Sano T; Setsu N; Kobayashi E; Kawai A
Yakugaku Zasshi; 2023; 143(6):541-544. PubMed ID: 37258187
[TBL] [Abstract][Full Text] [Related]
8. [Methylene blue in ifosfamide-induced encephalopathy].
Koschuth A; Späth-Schwalbe PE; Possinger K
Dtsch Med Wochenschr; 1996 Sep; 121(39):1210. PubMed ID: 8925751
[No Abstract] [Full Text] [Related]
9. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation.
Bubalo JS; Cherala G; McCune JS; Munar MY; Tse S; Maziarz R
J Clin Pharmacol; 2012 Apr; 52(4):586-94. PubMed ID: 21415280
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
Xiong J; Zhao G; Yang S; Chen J
Adv Ther; 2019 Feb; 36(2):355-364. PubMed ID: 30607545
[TBL] [Abstract][Full Text] [Related]
11. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide induced encephalopathy following chemotherapy of Non-Hodgkin's Lymphoma.
Jain S; Moger V; Kumari S; Varma S
Neurol India; 2001 Dec; 49(4):416. PubMed ID: 11799423
[No Abstract] [Full Text] [Related]
13. Effect of aprepitant on the pharmacokinetics of intravenous midazolam.
Majumdar AK; Yan KX; Selverian DV; Barlas S; Constanzer M; Dru J; McCrea JB; Ahmed T; Frick GS; Kraft WK; Petty KJ; Greenberg HE
J Clin Pharmacol; 2007 Jun; 47(6):744-50. PubMed ID: 17463213
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide-induced encephalopathy due to a novel formulation of ifosfamide.
Filhon B; Lacarra B; Hervouet C; Jaffray M; Schneider P; Vannier JP
Pediatr Blood Cancer; 2016 Feb; 63(2):372-3. PubMed ID: 26397980
[No Abstract] [Full Text] [Related]
15. [Errata: A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant].
Sano T; Setsu N; Kobayashi E; Kawai A
Yakugaku Zasshi; 2023; 143(7):621. PubMed ID: 37394457
[No Abstract] [Full Text] [Related]
16. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
Szabatura AH; Cirrone F; Harris C; McDonnell AM; Feng Y; Voit D; Neuberg D; Butrynski J; Fisher DC
J Oncol Pharm Pract; 2015 Jun; 21(3):188-93. PubMed ID: 24664476
[TBL] [Abstract][Full Text] [Related]
17. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
18. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy.
Küpfer A; Aeschlimann C; Cerny T
Eur J Clin Pharmacol; 1996; 50(4):249-52. PubMed ID: 8803513
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ifosfamide encephalopathy with intravenous thiamin.
Buesa JM; García-Teijido P; Losa R; Fra J
Clin Cancer Res; 2003 Oct; 9(12):4636-7. PubMed ID: 14555540
[No Abstract] [Full Text] [Related]
20. The Use of Continuous Veno-Venous Hemodiafiltration in the Management of Ifosfamide-induced Encephalopathy: A Case Report.
Yeo KK; HaDuong JH
J Pediatr Hematol Oncol; 2016 Aug; 38(6):489-90. PubMed ID: 26907647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
